Expanded partnership covers biosimilar candidates in immunology and oncology Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its...

Hukyndra® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumabExclusive partnership between Alvotech and STADA in Europe includes Hukyndra® and six...

On 14 September 2022, Alvotech filed Amendment No. 1 to the Registration Statement on Form F-1 (the “Preliminary Prospectus”), previously filed on 22 July 2022 with the U.S. Securities and Exchange Commission (the “SEC”). This Amendment No. 1 to the Form F-1 Registration Statement is attached as a P

On 13 September 2022, Alvotech filed Amendment No. 2 to the Registration Statement on Form F-1 (the “Preliminary Prospectus”), previously filed on 14 July 2022, and with Amendment No. 1 filed on 27 July 2022, with the U.S. Securities and Exchange Commission (the “SEC”). This Amendment No. 2 to the F

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Alvotech received communication...

Secured funding of approximately $185 million in gross proceeds through the merger with OACB (the “Business Combination”) and private placement investment in public equity (PIPE) financingDebuted as...

Alvotech releases ESG indicators covering both 2020 and 2021 Carbon neutrality for scope 1 and 2 emissions achieved in 2020 and 2021ESG portal is now available on the Company’s website at...